Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase CK2a1]
Substrate: NFKBIA

Description: NF-kappa-B inhibitor alpha (Major histocompatibility complex enhancer-binding protein MAD3) (I-kappa-B-alpha) (IkappaBalpha) (IkB-alpha).

Synonyms: IKBA, MAD3, NFKBI

Ensembl ID: ENSG00000100906

UniprotKB/SwissProt: IKBA_HUMAN (P25963)

Function: Inhibits NF-kappa-B by complexing with and trapping it in the cytoplasm. May be involved in regulation of transcriptional responses to NF-kappa-B, including cell adhesion, immune and proinflammatory responses, apoptosis, differentiation and growth. Controlled by sequential serine-phosphorylation, ubiquitination and degradation. Tyrosine-phosphorylation could only lead to dissociation from NF-kappa-B.

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Cytoplasm.
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of NFKBIA

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1NFKBIAIKBA_HUMANS32DDRHD S GLDSM 34.82%RSK3 HPRD:01235(in vitro;in vivo)  ViewAnalyzing
2NFKBIAIKBA_HUMANS32DDRHD S GLDSM 34.82%CK2a1-rs HPRD:01235(in vitro;in vivo)  ViewAnalyzing
3NFKBIAIKBA_HUMANS32DDRHD S GLDSM 34.82%IKK_group Phospho.ELM 7.0 ViewAnalyzing
4NFKBIAIKBA_HUMANS32DDRHD S GLDSM 34.82%CK2_group Phospho.ELM 7.0 ViewAnalyzing
5NFKBIAIKBA_HUMANS32DDRHD S GLDSM 34.82%CK2a1 HPRD:01235(in vitro;in vivo)  ViewAnalyzing
6NFKBIAIKBA_HUMANS32DDRHD S GLDSM 34.82%IKKb HPRD:01235(in vivo)  ViewAnalyzing
7NFKBIAIKBA_HUMANS32DDRHD S GLDSM 34.82%IKKa(IKK alpha) Phospho.ELM 7.0 ViewAnalyzing
8NFKBIAIKBA_HUMANS32DDRHD S GLDSM 34.82%O15382(Branched-chain aminotransferase 2) HPRD:01235(in vitro) ViewAnalyzing
9NFKBIAIKBA_HUMANS32DDRHD S GLDSM 34.82%PKR(EIF2AK2) Phospho.ELM 7.0 ViewAnalyzing
10NFKBIAIKBA_HUMANS32DDRHD S GLDSM 34.82%PKR HPRD:01235(in vitro;in vivo)  ViewAnalyzing
11NFKBIAIKBA_HUMANS32DDRHD S GLDSM 34.82%IKKe Swiss-Prot 55.0   ViewAnalyzing
12NFKBIAIKBA_HUMANS32DDRHD S GLDSM 34.82%IKKa Swiss-Prot 55.0   ViewAnalyzing
13NFKBIAIKBA_HUMANS36DSGLD S MKDEE 32.54%IKK_group Phospho.ELM 7.0 ViewAnalyzing
14NFKBIAIKBA_HUMANS36DSGLD S MKDEE 32.54%IKKa(IKK alpha) Phospho.ELM 7.0 ViewAnalyzing
15NFKBIAIKBA_HUMANS36DSGLD S MKDEE 32.54%TBK1 HPRD:01235(in vitro;in vivo)  ViewAnalyzing
16NFKBIAIKBA_HUMANS36DSGLD S MKDEE 32.54%CK2_group Phospho.ELM 7.0 ViewAnalyzing
17NFKBIAIKBA_HUMANS36DSGLD S MKDEE 32.54%IKKb HPRD:01235(in vitro)  ViewAnalyzing
18NFKBIAIKBA_HUMANS36DSGLD S MKDEE 32.54%IKKe Swiss-Prot 55.0   ViewAnalyzing
19NFKBIAIKBA_HUMANS36DSGLD S MKDEE 32.54%IKKb Swiss-Prot 55.0   ViewAnalyzing
20NFKBIAIKBA_HUMANS36DSGLD S MKDEE 32.54%IKKe HPRD:01235(in vitro)  ViewAnalyzing
21NFKBIAIKBA_HUMANS36DSGLD S MKDEE 32.54%IKKa Swiss-Prot 55.0   ViewAnalyzing
22NFKBIAIKBA_HUMANS36DSGLD S MKDEE 32.54%CK2a1 HPRD:01235(in vitro;in vivo)  ViewAnalyzing
23NFKBIAIKBA_HUMANS36DSGLD S MKDEE 32.54%CK2a1-rs HPRD:01235(in vitro;in vivo)  ViewAnalyzing
24NFKBIAIKBA_HUMANY42MKDEE Y EQMVK 14.93%Lck Phospho.ELM 7.0  ViewAnalyzing
25NFKBIAIKBA_HUMANY42MKDEE Y EQMVK 14.93%Tyr-kinases Swiss-Prot 55.0  ViewAnalyzing
26NFKBIAIKBA_HUMANY42MKDEE Y EQMVK 14.93%Src Phospho.ELM 7.0  ViewAnalyzing
27NFKBIAIKBA_HUMANY42MKDEE Y EQMVK 14.93%SRC HPRD:01235(in vitro;in vivo)  ViewAnalyzing
28NFKBIAIKBA_HUMANY42MKDEE Y EQMVK 14.93%LCK HPRD:01235(in vitro;in vivo)  ViewAnalyzing
29NFKBIAIKBA_HUMANS283QMLPE S EDEES 48.70%CK2a1-rs HPRD:01235(in vitro;in vivo)  ViewAnalyzing
30NFKBIAIKBA_HUMANS283QMLPE S EDEES 48.70%CK2_group Phospho.ELM 7.0 ViewAnalyzing
31NFKBIAIKBA_HUMANS283QMLPE S EDEES 48.70%CK2a1 HPRD:01235(in vitro;in vivo)  ViewAnalyzing
32NFKBIAIKBA_HUMANS283QMLPE S EDEES 48.70%CK2a1(CK2 alpha) Phospho.ELM 7.0 ViewAnalyzing
33NFKBIAIKBA_HUMANS288SEDEE S YDTES 26.68%CK2a1(CK2 alpha) Phospho.ELM 7.0 ViewAnalyzing
34NFKBIAIKBA_HUMANS288SEDEE S YDTES 26.68%CK2a1-rs HPRD:01235(in vitro;in vivo)  ViewAnalyzing
35NFKBIAIKBA_HUMANS288SEDEE S YDTES 26.68%CK2a1 HPRD:01235(in vitro;in vivo)  ViewAnalyzing
36NFKBIAIKBA_HUMANT291EESYD T ESEFT 32.93%CK2a1 HPRD:01235(in vitro;in vivo)  ViewAnalyzing
37NFKBIAIKBA_HUMANT291EESYD T ESEFT 32.93%CK2a1-rs HPRD:01235(in vitro;in vivo)  ViewAnalyzing
38NFKBIAIKBA_HUMANT291EESYD T ESEFT 32.93%CK2_group Phospho.ELM 7.0 ViewAnalyzing
39NFKBIAIKBA_HUMANT291EESYD T ESEFT 32.93%CK2a1(CK2 alpha) Phospho.ELM 7.0 ViewAnalyzing
40NFKBIAIKBA_HUMANS293SYDTE S EFTEF 39.85%CK2a1-rs HPRD:01235(in vitro;in vivo)  ViewAnalyzing
41NFKBIAIKBA_HUMANS293SYDTE S EFTEF 39.85%CK2a1 HPRD:01235(in vitro;in vivo)  ViewAnalyzing
42NFKBIAIKBA_HUMANS293SYDTE S EFTEF 39.85%CK2a1(CK2 alpha) Phospho.ELM 7.0 ViewAnalyzing
43NFKBIAIKBA_HUMANY305EDELP Y DDCVF 36.72%ABL1 Phospho.ELM 7.0  ViewAnalyzing